• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Dimethylsulfoxide-induced changes in a rat prostate adenocarcinoma.

作者信息

Wenger A S, Hall M, Mickey G H, Silverman L, Fried F A, Mickey D D

出版信息

Prostate. 1985;6(4):329-41. doi: 10.1002/pros.2990060402.

DOI:10.1002/pros.2990060402
PMID:4088948
Abstract

A variety of agents can induce mammalian tumor cell lines to acquire characteristics of the normal cell counterpart. Dimethylsulfoxide (DMSO) has been an effective differentiating agent in many tumor cell lines. In the present study a Dunning rat prostate tumor subline, MAT LyLu, available as an in vitro continuous cell culture was treated with 2.25% DMSO (vol/vol). Treated MAT LyLu cells had a decreased growth rate, saturation density, and clonogenicity, an increased doubling time, and alterations in enzyme activity and tumorigenicity when compared to untreated MAT LyLu cells. The cell viability of treated cells at the saturation density was greater than 90%. MAT LyLu cells treated with DMSO and then removed from DMSO (posttreated) when compared to untreated cells had similar growth rates, doubling times, clonogenicities, enzyme activities, and tumorigenicities. Posttreated MAT LyLu cells had a different growth pattern than untreated MAT LyLu cells. Posttreated cell viability at saturation density was greater than 90%. This investigation demonstrated that a rat prostate adenocarcinoma grown in medium containing 2.25% DMSO acquired characteristics consistent with differentiated prostate cells. Posttreated MAT LyLu cells were similar in many characteristics to untreated cells but were not identical. The alterations noted were not cytotoxic and were not completely reversible. The results of this study correlated with the observations of other investigators who have studied mammalian tumor cell lines exposed to DMSO.

摘要

相似文献

1
Dimethylsulfoxide-induced changes in a rat prostate adenocarcinoma.
Prostate. 1985;6(4):329-41. doi: 10.1002/pros.2990060402.
2
In vitro characterization of MAT LyLu: a Dunning rat prostate adenocarcinoma tumor subline.
J Urol. 1984 Jun;131(6):1232-6. doi: 10.1016/s0022-5347(17)50879-4.
3
Oncodevelopmental enzymes of the Dunning rat prostatic adenocarcinoma.邓宁大鼠前列腺腺癌的胚胎发育相关酶
Cancer Res. 1985 Sep;45(9):4053-9.
4
Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin.口服改性柑橘果胶对大鼠前列腺癌模型自发转移的抑制作用。
J Natl Cancer Inst. 1995 Mar 1;87(5):348-53. doi: 10.1093/jnci/87.5.348.
5
Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells.蛋白激酶C-ζ(PKC-ζ)的过表达抑制了邓宁R-3327 MAT-LyLu大鼠前列腺癌细胞的侵袭和转移能力。
Cancer Res. 1996 Sep 15;56(18):4137-41.
6
Inhibitory effects of dunning rat prostate tumor fluid on proliferation of the metastatic MAT-LyLu cell line.邓恩大鼠前列腺肿瘤液对转移性MAT-LyLu细胞系增殖的抑制作用。
Asian Pac J Cancer Prev. 2015;16(2):831-6. doi: 10.7314/apjcp.2015.16.2.831.
7
Effect of dimethylsulfoxide on the proliferation and glycosaminoglycan synthesis of rat prostate adenocarcinoma cells (PAIII) in vitro: isolation and characterization of DMSO-resistant cells.二甲基亚砜对大鼠前列腺腺癌细胞(PAIII)体外增殖及糖胺聚糖合成的影响:二甲基亚砜抗性细胞的分离与鉴定
Prostate. 1991;18(1):47-58. doi: 10.1002/pros.2990180105.
8
Re: In vitro characterization of Mat LyLu: a Dunning rat prostate adenocarcinoma tumor subline.
J Urol. 1985 Apr;133(4):691-2. doi: 10.1016/s0022-5347(17)49162-2.
9
The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor.一种新鉴定出的、具有高转移性的邓宁R 3327大鼠前列腺腺癌系统的特征:MAT LyLu肿瘤。
Invest Urol. 1981 Jul;19(1):20-3.
10
Biometric assessment of prostate cancer's metastatic potential.
World J Urol. 1994;12(6):304-7. doi: 10.1007/BF00184108.